Q2 revenue up 37%, PAT jumps to Rs 575 mn consolidated; auditor changed mid-year

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemAuditor Mid Year ChangeNegative Operating CashflowResults View source PDF Explain this filing

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+13.9%Reaction day

₹1398.80

prior close

₹1431.30

announcement price

In-mkt

timing

Nifty Smallcap 250market+2.2%+11.7% vs market

Pharmaceuticals peers, median of 173sector+2.0%+11.9% vs sector

On the reaction day the stock moved 11.7 pts more than Nifty Smallcap 250 and 11.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.5

10m

+3.6

15m

+3.8

30m

+4.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+13.9+2.2+11.7+2.0+11.9

Next day

+12.3+2.5+9.8+2.6+9.7

+12.2+3.2+9.0+2.6+9.6

+13.3pendingpending+1.9+11.4

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone Q2 revenue rose 37% to Rs 5,145 mn and PAT to Rs 862 mn from Rs 371 mn. Consolidated revenue rose 37% to Rs 5,162 mn and PAT jumped to Rs 575 mn from Rs 105 mn; H1 PAT was Rs 825 mn. H1 consolidated results include Rs 60.67 mn exceptional losses. Operating cash flow was negative Rs 192 mn in H1. B S R & Co. LLP reviewed Q2, while the predecessor auditor reviewed the June 2026 quarter.

Likely market impact

Strong growth should support the stock, but the mid-year auditor change and negative operating cash flow are concerns.